Jump to navigation Jump to search
Clinical data
Trade namesTrobalt, Potiga
[[Regulation of therapeutic goods |Template:Engvar data]]
  • US: C (Risk not ruled out)
Routes of
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding60–80%
MetabolismHepatic glucuronidation and acetylation. CYP not involved
Elimination half-life8 hours (mean)[1]
ExcretionRenal (84%)
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass303.331 g/mol
3D model (JSmol)

WikiDoc Resources for Retigabine


Most recent articles on Retigabine

Most cited articles on Retigabine

Review articles on Retigabine

Articles on Retigabine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Retigabine

Images of Retigabine

Photos of Retigabine

Podcasts & MP3s on Retigabine

Videos on Retigabine

Evidence Based Medicine

Cochrane Collaboration on Retigabine

Bandolier on Retigabine

TRIP on Retigabine

Clinical Trials

Ongoing Trials on Retigabine at Clinical

Trial results on Retigabine

Clinical Trials on Retigabine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Retigabine

NICE Guidance on Retigabine


FDA on Retigabine

CDC on Retigabine


Books on Retigabine


Retigabine in the news

Be alerted to news on Retigabine

News trends on Retigabine


Blogs on Retigabine


Definitions of Retigabine

Patient Resources / Community

Patient resources on Retigabine

Discussion groups on Retigabine

Patient Handouts on Retigabine

Directions to Hospitals Treating Retigabine

Risk calculators and risk factors for Retigabine

Healthcare Provider Resources

Symptoms of Retigabine

Causes & Risk Factors for Retigabine

Diagnostic studies for Retigabine

Treatment of Retigabine

Continuing Medical Education (CME)

CME Programs on Retigabine


Retigabine en Espanol

Retigabine en Francais


Retigabine in the Marketplace

Patents on Retigabine

Experimental / Informatics

List of terms related to Retigabine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Retigabine (INN) or ezogabine (USAN), codenamed D-23129, is an anticonvulsant used as a treatment for partial epilepsies. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011.

Retigabine works primarily as a potassium channel opener—that is, by activating a certain family of voltage-gated potassium channels in the brain.[2][3][4] This mechanism of action is unique among antiepileptic drugs, and may hold promise for the treatment of other neurologic conditions, including migraine and neuropathic pain.


Among the newer anticonvulsants, retigabine was one of the most widely studied in the preclinical setting: it was the subject of over 100 published studies before clinical trials began. In preclinical tests, it was found to have a very broad spectrum of activity—being effective in nearly all the animal models of seizures and epilepsy used: retigabine suppresses seizures induced by electroshock, electrical kindling of the amygdala, pentylenetetrazol, kainate, NMDA, and picrotoxin.[5] Researchers hoped this wide-ranging activity would translate to studies in humans as well.[6]

Clinical trials

In a double-blind, randomized, placebo-controlled Phase II clinical trial, retigabine was added to the treatment regimen of 399 participants with partial seizures that were refractory to therapy with other antiepileptic drugs. The frequency with which seizures occurred was significantly reduced (by 23 to 35%) in participants receiving retigabine, and approximately one fourth to one third of participants had their seizure frequency reduced by more than 50%. Higher doses were associated with a greater response to treatment.[6][7][8]

A Phase II trial meant to assess the safety and efficacy of retigabine for treating postherpetic neuralgia was completed in 2009, but failed to meet its primary endpoint. Preliminary results were reported by Valeant as "inconclusive".[9]

Regulatory approval

The U.S. Food and Drug Administration accepted Valeant's New Drug Application for retigabine on December 30, 2009.[10] The FDA Peripheral and Central Nervous System Drugs Advisory Committee met on August 11, 2010 to discuss the process and unanimously recommended approval of Potiga for the intended indication (add-on treatment of partial seizures in adults).[11][12] However, the possibility of urinary retention as an adverse effect was considered a significant concern, and the panel's members recommended that some sort of monitoring strategy be used to identify patients at risk of bladder dysfunction.[11] Potiga was approved by the FDA on June 10, 2010, and is set to become available on the U.S. market after scheduling by the Drug Enforcement Administration.[13]

In December 2011, the U.S. Drug Enforcement Administration (DEA) placed the substance into Schedule V of the Controlled Substances Act (CSA), the category for substances with a comparatively low potential for abuse. This became effective 15 December 2011.[14]

Adverse effects

The adverse effects found in the Phase II trial mainly affected the central nervous system, and appeared to be dose-related.[6] The most common adverse effects were drowsiness, dizziness and vertigo, confusion, and slurred speech.[8] Less common side effects included tremor, memory loss, gait disturbances, and double vision.[7]

Psychiatric symptoms and difficulty urinating have also been reported, with most cases occurring in the first 2 months of treatment.[13][15]


Retigabine appears to be free of drug interactions with most commonly used anticonvulsants. It may increase metabolism of lamotrigine (Lamictal), whereas phenytoin (Dilantin) and carbamazepine (CBZ, Tegretol) increase the clearance of retigabine.[15][16]

Concomitant use of retigabine and digoxin may increase serum concentration of the latter. In vitro studies suggest that the main metabolite of retigabine acts as a P-glycoprotein inhibitor, and may thus increase absorption and reduce elimination of digoxin.[15]


Retigabine is quickly absorbed, and reaches maximum plasma concentrations between half an hour and 2 hours after a single oral dose. It has a moderately high oral bioavailability (50–60%), a high volume of distribution (6.2 L/kg), and a terminal half-life of 8 to 11 hours.[16] Retigabine requires thrice-daily dosing due to its short half-life.[6][8][15]

Retigabine is metabolized in the liver, by N-glucuronidation and acetylation. The cytochrome P450 system is not involved. Retigabine and its metabolites are excreted almost completely (84%) by the kidneys.[16][15]

Mechanism of action

Retigabine acts as a neuronal KCNQ/Kv7 potassium channel opener, a mechanism of action markedly different from than of any current anticonvulsants.[2][3][4] This mechanism of action is similar to that of flupirtine,[17] which is used mainly for its analgesic properties.


The International Nonproprietary Name "retigabine" was initially published as being under consideration by WHO in 1996.[18] This was later adopted as the recommended International Nonproprietary Name (rINN) for the drug, and, in 2005 or 2006, the USAN Council—a program sponsored by the American Medical Association, the United States Pharmacopeial Convention, and the American Pharmacists Association that chooses nonproprietary names for drug sold in the United States—adopted the same name.[19] In 2010, however, the USAN Council rescinded its previous decision and assigned "ezogabine" as the United States Adopted Name for the drug.[20] The drug will thus be known as "ezogabine" in the United States and "retigabine" elsewhere.


  1. Ferron GM, Paul J, Fruncillo R; et al. (2002). "Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers". Journal of Clinical Pharmacology. 42 (2): 175–82. doi:10.1177/00912700222011210. PMID 11831540. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 Rundfeldt C (1997). "The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells". European Journal of Pharmacology. 336 (2–3): 243–9. doi:10.1016/S0014-2999(97)01249-1. PMID 9384239. Unknown parameter |month= ignored (help)
  3. 3.0 3.1 Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA (2000). "Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine". Molecular Pharmacology. 58 (2): 253–62. PMID 10908292. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 Rogawski MA, Bazil CW (2008). "New Molecular Targets for Antiepileptic Drugs: α2δ, SV2A, and Kv7/KCNQ/M Potassium Channels". Current Neurology and Neuroscience Reports. 8 (4): 345–52. doi:10.1007/s11910-008-0053-7. PMC 2587091. PMID 18590620. Unknown parameter |month= ignored (help)
  5. Rogawski MA (2006). "Diverse Mechanisms of Antiepileptic Drugs in the Development Pipeline". Epilepsy Research. 69 (3): 273–94. doi:10.1016/j.eplepsyres.2006.02.004. PMC 1562526. PMID 16621450. Unknown parameter |month= ignored (help)
  6. 6.0 6.1 6.2 6.3 Ben-Menachem E (2007). "Retigabine: Has the Orphan Found a Home?". Epilepsy Currents. 7 (6): 153–4. doi:10.1111/j.1535-7511.2007.00209.x. PMC 2096728. PMID 18049722.
  7. 7.0 7.1 Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM (2007). "Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures". Neurology. 68 (15): 1197–204. doi:10.1212/01.wnl.0000259034.45049.00. PMID 17420403. Unknown parameter |month= ignored (help)
  8. 8.0 8.1 8.2 Plosker GL, Scott LJ (2006). "Retigabine: in partial seizures". CNS Drugs. 20 (7): 601–8, discussion 609–10. PMID 16800718.
  9. "Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)" (Press release). PRNewswire. 2009-08-24. Retrieved 2011-06-13.
  10. "Retigabine NDA accepted for filing" (Press release). PRNewswire. 2009-12-30. Retrieved 2010-07-19.
  11. 11.0 11.1 Lowry F (2010-08-12). "Epilepsy drug exogabine gets green light from FDA Advisory Panel". Medscape. Retrieved 2010-08-13.
  12. [No authors listed] (2010-06-25). "August 11, 2010: Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement". U.S. Food and Drug Administration. Retrieved 2010-07-19.
  13. 13.0 13.1 Hitt E (2011-06-13). "FDA approves ezogabine for seizures in adults". Medscape. Retrieved 2011-06-13.
  14. U.S. Drug Enforcement Administration (15 December 2011). "Schedules of Controlled Substances: Placement of Ezogabine Into Schedule V" (PDF). Federal Register. 76 (241).
  15. 15.0 15.1 15.2 15.3 15.4 "Trobalt – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. 2011-05-05. Retrieved 2011-06-13.
  16. 16.0 16.1 16.2 Łuszczki JJ (2009). "Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions" (PDF). Pharmacology Reports. 61 (2): 197–216. PMID 19443931.
  17. Brown, DA; Passmore, GM (2009). "Neural KCNQ (Kv7) channels". British Journal of Pharmacology. 156 (8): 1185–95. doi:10.1111/j.1476-5381.2009.00111.x. PMC 2697739. PMID 19298256.
  18. World Health Organization (1996). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 215.
  19. [No authors listed] (2005–06). "Statement on a nonproprietary name adopted by the USAN council: Retigabine" (PDF). American Medical Association. Retrieved 2010-07-19. Check date values in: |year= (help)
  20. [No authors listed] (2010). "Statement on a nonproprietary name adopted by the USAN council: Ezogabine" (PDF). American Medical Association. Retrieved 2010-07-19.

Further reading

External links